Alkermes plc. Cost of Goods Sold (Deprecated 2018-01-31)
Alkermes plc. (ALKS) reported Cost of Goods Sold (Deprecated 2018-01-31) of $154.75 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-16.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-02-16
- Alkermes plc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $38.51M, a 10.16% increase year-over-year.
- Alkermes plc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $36.05M, a 1.69% increase year-over-year.
- Alkermes plc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $39.77M, a 16.99% increase year-over-year.
- Alkermes plc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $40.41M, a 45.83% increase year-over-year.
- Alkermes plc. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $154.75M, a 17.13% increase from fiscal 2016.
- Alkermes plc. cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $132.12M, a 4.94% decline from fiscal 2015.
- Alkermes plc. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $138.99M, a 20.95% decline from fiscal 2014.
- Alkermes plc. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $175.83M.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $38.51M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $74.56M derived: sum of 2 quarters · filed 2018-02-16 | $114.34M derived: sum of 3 quarters · filed 2018-02-16 | $154.75M 10-K · filed 2018-02-16 |
| 2017-09-30 | $36.05M 10-Q · filed 2017-10-26 | $75.83M derived: sum of 2 quarters · filed 2017-10-26 | $116.24M 10-Q · filed 2017-10-26 | $151.20M derived: sum of 4 quarters · filed 2018-02-16 |
| 2017-06-30 | $39.77M 10-Q · filed 2017-07-27 | $80.19M 10-Q · filed 2017-07-27 | $115.14M derived: sum of 3 quarters · filed 2018-02-16 | $150.60M derived: sum of 4 quarters · filed 2018-02-16 |
| 2017-03-31 | $40.41M 10-Q · filed 2017-04-27 | $75.37M derived: sum of 2 quarters · filed 2018-02-16 | $110.83M derived: sum of 3 quarters · filed 2018-02-16 | $144.82M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-12-31 | $34.96M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $70.41M derived: sum of 2 quarters · filed 2018-02-16 | $104.41M derived: sum of 3 quarters · filed 2018-02-16 | $132.12M 10-K · filed 2018-02-16 |
| 2016-09-30 | $35.46M 10-Q · filed 2017-10-26 | $69.45M derived: sum of 2 quarters · filed 2017-10-26 | $97.17M 10-Q · filed 2017-10-26 | $131.96M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $34.00M 10-Q · filed 2017-07-27 | $61.71M 10-Q · filed 2017-07-27 | $96.50M derived: sum of 3 quarters · filed 2018-02-16 | $130.31M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $27.71M 10-Q · filed 2017-04-27 | $62.50M derived: sum of 2 quarters · filed 2018-02-16 | $96.31M derived: sum of 3 quarters · filed 2018-02-16 | $126.73M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $34.79M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $68.60M derived: sum of 2 quarters · filed 2018-02-16 | $99.02M derived: sum of 3 quarters · filed 2018-02-16 | $138.99M 10-K · filed 2018-02-16 |
| 2015-09-30 | $33.81M 10-Q · filed 2016-11-02 | $64.22M derived: sum of 2 quarters · filed 2016-11-02 | $104.20M 10-Q · filed 2016-11-02 | $150.57M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $30.42M 10-Q · filed 2016-07-28 | $70.39M 10-Q · filed 2016-07-28 | $116.76M derived: sum of 3 quarters · filed 2017-02-17 | $164.09M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $39.97M 10-Q · filed 2016-04-28 | $86.34M derived: sum of 2 quarters · filed 2017-02-17 | $133.68M derived: sum of 3 quarters · filed 2017-02-17 | $176.97M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $46.37M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $93.70M derived: sum of 2 quarters · filed 2017-02-17 | $136.99M derived: sum of 3 quarters · filed 2017-02-17 | $175.83M 10-K · filed 2017-02-17 |
| 2014-09-30 | $47.34M 10-Q · filed 2015-10-29 | $90.63M derived: sum of 2 quarters · filed 2015-10-29 | $129.46M 10-Q · filed 2015-10-29 | $172.36M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $43.29M 10-Q · filed 2015-07-30 | $82.13M 10-Q · filed 2015-07-30 | $125.02M derived: sum of 3 quarters · filed 2016-02-25 | $170.44M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $38.84M 10-Q · filed 2015-04-30 | $81.73M derived: sum of 2 quarters · filed 2016-02-25 | $127.15M derived: sum of 3 quarters · filed 2016-02-25 | $173.15M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $42.89M derived: 10-K 9 month − 10-Q 6 month · filed 2016-02-25 | $88.31M derived: sum of 2 quarters · filed 2016-02-25 | $134.31M 10-K · filed 2016-02-25 | $182.30M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-09-30 | $45.42M 10-Q · filed 2014-10-29 | $91.41M 10-Q · filed 2013-10-31 | $139.41M 10-Q · filed 2014-10-29 | $178.32M derived: sum of 4 quarters · filed 2014-10-29 |
| 2013-06-30 | $45.99M 10-Q · filed 2014-07-31 | $93.98M 10-Q · filed 2014-07-31 | $132.90M derived: sum of 3 quarters · filed 2014-07-31 | $174.39M derived: sum of 4 quarters · filed 2014-07-31 |
| 2013-03-31 | $47.99M 10-Q · filed 2014-04-30 | $86.91M derived: sum of 2 quarters · filed 2014-04-30 | $128.40M derived: sum of 3 quarters · filed 2014-04-30 | $170.47M 10-K · filed 2015-02-24 |
| 2012-12-31 | $38.91M 10-Q · filed 2013-01-31 | $80.41M derived: sum of 2 quarters · filed 2013-10-31 | $122.47M 10-Q · filed 2013-01-31 | $173.55M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-09-30 | $41.49M 10-Q · filed 2013-10-31 | $83.56M 10-Q · filed 2013-10-31 | $134.64M derived: sum of 3 quarters · filed 2014-02-27 | $177.39M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $42.07M 10-Q · filed 2013-07-25 | $93.15M derived: sum of 2 quarters · filed 2014-02-27 | $135.90M derived: sum of 3 quarters · filed 2014-02-27 | $153.43M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $51.08M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $93.83M derived: sum of 2 quarters · filed 2014-02-27 | $111.36M derived: sum of 3 quarters · filed 2014-02-27 | $127.58M 10-KT · filed 2014-02-27 |
| 2011-12-31 | $42.75M 10-Q · filed 2013-01-31 | $60.28M derived: sum of 2 quarters · filed 2013-01-31 | $76.50M 10-Q · filed 2013-01-31 | $89.25M derived: sum of 4 quarters · filed 2013-05-23 |
| 2011-09-30 | $17.53M 10-Q · filed 2012-11-01 | $33.75M 10-Q · filed 2012-11-01 | $46.50M derived: sum of 3 quarters · filed 2013-05-23 | $59.36M derived: sum of 4 quarters · filed 2013-05-23 |
| 2011-06-30 | $16.22M 10-Q · filed 2012-07-26 | $28.97M derived: sum of 2 quarters · filed 2013-05-23 | $41.83M derived: sum of 3 quarters · filed 2013-05-23 | $55.74M derived: sum of 4 quarters · filed 2013-05-23 |
| 2011-03-31 | $12.75M derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | $25.61M derived: sum of 2 quarters · filed 2013-05-23 | $39.52M derived: sum of 3 quarters · filed 2013-05-23 | $52.19M 10-K · filed 2013-05-23 |
| 2010-12-31 | $12.86M 10-Q · filed 2012-02-02 | $26.77M derived: sum of 2 quarters · filed 2012-02-02 | $39.44M 10-Q · filed 2012-02-02 | |
| 2010-09-30 | $13.91M 10-Q · filed 2011-11-03 | $26.58M 10-Q · filed 2011-11-03 | ||
| 2010-03-31 | $49.44M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |